Intellia Therapeutics to Present at Jefferies Gene Editing/Therapy Summit

CAMBRIDGE, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Medical Officer John Leonard, M.D., will participate in a panel discussion and present a company overview at the Jefferies Gene Editing/Therapy Summit on Tuesday, October 11, 2016.     

Details of the presentation are as follows:

Jefferies Gene Editing/Therapy Summit
Date: Tuesday, October 11, 2016
Location: New York, New York
Times: Panel discussion at 10:00 am ET with company presentation to follow at 2:00 pm ET.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.

CONTACT: Media Contact:

Jennifer Mound Smoter
Chief External Affairs & Communications Officer
+1 224-804-4462
jenn.smoter@intelliatx.com

Investor Contacts:

John Graziano
Trout Group
+1 646-378-2942
jgraziano@troutgroup.com

Chad Rubin
Trout Group
+1 646-378-2947
crubin@troutgroup.com

NPHC Disclosure: We hold not shares and will not be receiving any shares. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we don’t own shares, will not be buying shares and will not be selling shares. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. We expect to be compensated up to five thousand seven hundred dollars for coverage, assuming three months coverage. StockGuru – McKinney, Texas 75070 – (469) 358-5200.

Logo Header Menu